Waverton Investment Management Ltd Grows Stake in Eli Lilly And Co (LLY)

Waverton Investment Management Ltd lifted its holdings in Eli Lilly And Co (NYSE:LLY) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,724 shares of the company’s stock after acquiring an additional 238 shares during the quarter. Waverton Investment Management Ltd’s holdings in Eli Lilly And Co were worth $1,472,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Balasa Dinverno & Foltz LLC boosted its holdings in Eli Lilly And Co by 15.9% during the third quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after buying an additional 499 shares in the last quarter. Arizona State Retirement System boosted its holdings in Eli Lilly And Co by 0.8% during the third quarter. Arizona State Retirement System now owns 278,567 shares of the company’s stock worth $29,893,000 after buying an additional 2,174 shares in the last quarter. Blair William & Co. IL boosted its holdings in Eli Lilly And Co by 4.0% during the third quarter. Blair William & Co. IL now owns 245,801 shares of the company’s stock worth $26,377,000 after buying an additional 9,532 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Eli Lilly And Co by 26.2% during the third quarter. Russell Investments Group Ltd. now owns 906,840 shares of the company’s stock valued at $97,186,000 after purchasing an additional 188,150 shares in the last quarter. Finally, FMR LLC lifted its holdings in Eli Lilly And Co by 172.9% during the second quarter. FMR LLC now owns 1,188,301 shares of the company’s stock valued at $101,398,000 after purchasing an additional 752,864 shares in the last quarter. Hedge funds and other institutional investors own 77.02% of the company’s stock.

Shares of LLY traded down $1.49 during trading on Monday, reaching $114.69. 472,637 shares of the company traded hands, compared to its average volume of 4,772,150. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $119.84. The stock has a market cap of $124.16 billion, a PE ratio of 26.80, a P/E/G ratio of 1.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the business earned $1.05 earnings per share. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly And Co will post 5.59 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.25%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.

In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the sale, the insider now directly owns 3,148,647 shares in the company, valued at $44,081,058. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 202,540 shares of the firm’s stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $113.48, for a total transaction of $22,984,239.20. Following the completion of the transaction, the insider now directly owns 118,814,164 shares of the company’s stock, valued at approximately $13,483,031,330.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,702,736 shares of company stock valued at $124,427,811. Company insiders own 0.11% of the company’s stock.

Several equities analysts have issued reports on LLY shares. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday, November 6th. Cantor Fitzgerald set a $110.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, September 17th. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 price objective on the stock in a report on Tuesday, October 9th. Guggenheim started coverage on shares of Eli Lilly And Co in a report on Monday, October 8th. They set a “buy” rating on the stock. Finally, ValuEngine raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a report on Monday, October 8th. Ten equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $111.50.

TRADEMARK VIOLATION WARNING: “Waverton Investment Management Ltd Grows Stake in Eli Lilly And Co (LLY)” was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://theenterpriseleader.com/2019/01/14/waverton-investment-management-ltd-grows-stake-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Back-End Load

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply